AFM
FOMX

Anson Funds Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Anson Funds Management’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-79,061
Closed -$284K – 66
2018
Q4 		$284K Buy
+79,061
New +$344K 0.17% 34

Other funds holding FOMX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Anson Funds Management's FOMX Position: Q1 2019 in Review

Anson Funds Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2019, closing a stake of 79,061 shares — an estimated $284K sold.

Anson Funds Management first reported a position in FOMX in Q4 2018 and held it in 1 quarter. The position peaked at $284K in Q4 2018. 62 funds tracked by Wall St. Rank hold FOMX as of Q1 2019.

  • Anson Funds Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2019 after selling out during the quarter.
  • Anson Funds Management sold 79,061 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2019, an estimated $284K.
  • Anson Funds Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q4 2018 and held it in 1 quarter.
  • Anson Funds Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $284K in Q4 2018.
  • 62 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2019.

Based on Anson Funds Management's 13F filing for Q1 2019, filed 15 May 2019.